A compound related to the antimalarial drug quinine has been found to inhibit and kill drug resistant bacteria responsible for serious blood and lung infections following surgery.
A new test for diagnosing bone fragility has been approved for marketing in Europe. This blood test is being launched by ProAxsis, a global diagnostics company based in Northern Ireland.